Clinical Observation Of Modified Gancao Xiexin Decoction In Treating Airway Mucus Hypersecretion Bronchiectasis With Lung-Heat And Spleen-Deficiency Syndrome In Acute Phase

Objective:By observing the clinical efficacy,TCM syndrome score,cough and sputum assessment questionnaire(CASA-Q)score,24-hour sputum volume and serum inflammatory factors of patients with acute lung heat and spleen deficiency syndrome of airway mucus hypersecretion bronchiectasis treated with modified Gancao Xiexin Decoction,the clinical efficacy of modified Gancao Xiexin Decoction in the treatment of acute lung heat and spleen deficiency syndrome of airway mucus hypersecretion bronchiectasis and its effect on serum inflammatory factors were evaluated.At the same time,it provides theoretical and clinical basis for the clinical application and further promotion of the party.Methods: 70 patients with lung heat and spleen deficiency syndrome in acute stage of bronchiectasis were randomly divided into control group and observation group.The control group was treated with conventional western medicine according to the consensus of Chinese experts on diagnosis and treatment of adult bronchiectasis(2021)and the ninth edition of Internal Medicine.The observation group was treated with modified licorice Xiexin decoction for 10 days.The clinical efficacy,TCM syndrome score,cough and expectoration assessment questionnaire(CASA-Q)and other improvements of the control group and the observation group before and after treatment were observed,and the serum white blood cells,neutrophils,CRP Changes of IL-6 and 24-hour sputum volume.Results:(1)Comparison of clinical efficacy between the two groups: the total effective rate of the treatment group was 87.5%,and the total effective rate of the control group was 78.79%,P<0.05,the difference was statistically significant.(2)Comparison of TCM syndrome score between the two groups:(1)The total score of TCM syndromes: There was no significant difference in the total score of TCM syndromes between the two groups before treatment(P>0.05),which was comparable.Comparison between groups: After treatment,the total scores of TCM syndromes in the treatment group and the control group were lower than those before treatment,and the difference was statistically significant(P<0.05).Intra-group comparison: After treatment,the total score of TCM syndromes in the treatment group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).(2)Single TCM symptom score: Before treatment,there was no significant difference between the two groups in cough,sputum,chest tightness,fatigue,epigastric distention,blood in sputum and loose stool(P>0.05).The scores of cough,expectoration,chest tightness,fatigue,epigastric distention,bloody sputum and loose stool before and after treatment in the treatment group were compared(P<0.05),and the difference was statistically significant.The scores of cough,expectoration,chest tightness,fatigue,epigastric distention,bloody sputum and loose stool in the control group before and after treatment were compared(P<0.05),and the difference was statistically significant.After treatment,the scores of cough,expectoration,chest tightness,fatigue,epigastric distention,bloody sputum and loose stool in the treatment group were significantly lower than those in the control group(P<0.05),and the difference was statistically significant.(3)Comparison of serum inflammatory factors between the two groups:There was no significant difference between the two groups before treatment in leukocyte count,neutrophil percentage,CRP and IL-6(P > 0.05).Compared with the two groups after treatment,both groups can reduce the white blood cell count,neutrophil percentage,CRP and IL-6 levels,but the treatment group is better than the control group in improving the white blood cell count,neutrophil percentage,CRP and IL-6 levels(P<0.05).(4)Comparison of cough and expectoration questionnaire score and24-hour sputum volume: There was no statistically significant difference between the two groups before treatment(P>0.05),which was comparable.After treatment,the score of cough and expectoration questionnaire in the treatment group and the control group decreased significantly compared with that before treatment(P<0.05).After treatment,the improvement of cough and expectoration questionnaire score in the treatment group was better than that in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in sputum volume between the two groups before treatment(P>0.05),which was comparable.After treatment,the level of sputum volume in the treatment group and the control group decreased significantly compared with that before treatment(P<0.05).After treatment,the improvement of sputum volume in the treatment group was better than that in the control group,and the difference was statistically significant(P<0.05).(5)Safety analysis: During the trial,no adverse drug reactions occurred in the two groups of patients,and no obvious abnormalities were found in body temperature,respiration,pulse,blood pressure,three routine tests,liver and kidney function,electrocardiogram,etc.Conclusion: 1.The modified licorice Xiexin decoction can improve the clinical symptoms of patients with lung heat and spleen deficiency syndrome in the acute stage of bronchiectasis,and can reduce the sputum output of patients;2.The modified licorice Xiexin decoction can improve the white blood cell count,neutrophil percentage,CRP and IL-6 related inflammatory indicators in patients with lung heat and spleen deficiency syndrome in the acute stage of bronchiectasis.